Skip to main content

Advertisement

SpringerLink
Log in

Management of medically refractory prolactinoma

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Resistance to dopamine agonists is defined here as failure to normalize prolactin levels and failure to decrease macroprolactinoma size by ≥50 %. Failure to normalize prolactin levels is found in about 25 % of patients treated with bromocriptine and 10–15 % of those treated with cabergoline. Failure to achieve at least a 50 % reduction in tumor size occurs in about one-third of those treated with bromocriptine and 10–15 % of those treated with cabergoline. Treatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. Transsphenoidal surgery is also an option. Clomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement [estrogen or testosterone] may cause a decrease in efficacy of the dopamine agonist. Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches. Temozolomide may be useful as a last resort for aggressive, invasive tumors refractory to other medical and ablative therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gillam MP, Molitch MP, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534

    Article  CAS  PubMed  Google Scholar 

  2. Melmed S, Casaneuva FF, Hoffman AR, Kleinberg D, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:273–288

    Article  CAS  PubMed  Google Scholar 

  3. Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114:1369–1379

    CAS  PubMed  Google Scholar 

  4. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509

    Article  CAS  PubMed  Google Scholar 

  5. DiSarno A, Landi ML, Cappabianca P, DiSalle F, Rossi FW, Pivonello R et al (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261

    Article  CAS  Google Scholar 

  6. Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43–52

    Article  CAS  PubMed  Google Scholar 

  7. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AMR, Ballarion C, Stalldecker G, Becu-Villalobis D (2009) Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol 20:35–40

    Article  CAS  PubMed  Google Scholar 

  8. Behan LA, Draman MS, Moran C, King T, Crowley RK, O’Sullivan EP et al (2011) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 14:362–366

    Article  CAS  PubMed  Google Scholar 

  9. Vroom L, Jaffrain-Rea M-L, Petrossians P, Tamagno G, Chanson P, Vilar L et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662

    Article  Google Scholar 

  10. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH (1997) Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 82:2962–2965

    Article  CAS  PubMed  Google Scholar 

  11. Maurer RA (1982) Estradiol regulates the transcription of the prolactin gene. J Biol Chem 257:2133–2136

    CAS  PubMed  Google Scholar 

  12. Lloyd GM, Meares JD, Jacobi J (1975) Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255:497–498

    Article  CAS  PubMed  Google Scholar 

  13. Raymond V, Beaulieu M, Labrie F, Boissier J (1979) Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173–1175

    Article  Google Scholar 

  14. Pasqualini C, Bojda F, Kerdelhué B (1986) Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomized rats. Endocrinology 119:2484–2489

    Article  CAS  PubMed  Google Scholar 

  15. Aoki MDP, Aoki A, Maldonado CA (2001) Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol 116:215–222

    Article  CAS  PubMed  Google Scholar 

  16. Páez-Pereda M, Giacomini D, Refojo D, Hagashima AC, Hopfner U, Grübler Y et al (2003) Involvement of bone morphogenetic protein 4 [BMP-4] in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 100:1034–1039

    Article  PubMed Central  PubMed  Google Scholar 

  17. Lamberts SWJ, Verleun T, Hofland L, Oosterom R (1986) Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 63:1342–1347

    Article  CAS  PubMed  Google Scholar 

  18. Molitch ME (2011) Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 25:885–896

    Article  CAS  PubMed  Google Scholar 

  19. Corenblum B, Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59:671–673

    CAS  PubMed  Google Scholar 

  20. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391–394

    Article  CAS  PubMed  Google Scholar 

  21. Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447–4451

    Article  CAS  PubMed  Google Scholar 

  22. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331:904–909

    Article  CAS  PubMed  Google Scholar 

  23. Pascal-Vigneron V, Weryha G, Bose M, Leclere J (1995) Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 24:754–757

    Google Scholar 

  24. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721–4727

    Article  CAS  PubMed  Google Scholar 

  25. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747–752

    Article  CAS  PubMed  Google Scholar 

  26. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R et al (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705

    Article  CAS  PubMed  Google Scholar 

  27. Colao A, DiSarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2246–2252

    Google Scholar 

  28. Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM (1980) A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 50:1026–1033

    Article  CAS  PubMed  Google Scholar 

  29. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D et al (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314–322

    Article  CAS  PubMed  Google Scholar 

  30. Passos VQ, Fortes MAHZ, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89:163–170

    Article  CAS  PubMed  Google Scholar 

  31. Shimazu S, Shimatsu A, Yamada S, Inoshita N, Nagamura Y, Usui T, Tsukada T (2012) Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol 166:383–390

    Article  CAS  PubMed  Google Scholar 

  32. Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD et al (2010) Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 99:25–32

    Article  CAS  PubMed  Google Scholar 

  33. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A (1996) Alteration of Gα subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 8:737–746

    Article  CAS  PubMed  Google Scholar 

  34. Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S et al (2008) Dopamine D2 Receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenetics J 8:357–363

    Article  CAS  Google Scholar 

  35. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al (2003) Synonymous mutations in the human dopamine receptor D2 [DRD2] affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205–216

    Article  CAS  PubMed  Google Scholar 

  36. Olafsdottir A, Schlechte J (2006) Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2:552–561

    Article  CAS  PubMed  Google Scholar 

  37. Colao A, DiSarno A, Sarnacchiaro F, Ferone D, DiRenzo G, Merola B et al (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876–883

    Article  CAS  PubMed  Google Scholar 

  38. Iyer P, Molitch ME (2011) Positive prolactin response to bromocriptine in two patients with cabergoline resistant prolactinomas. Endocr Pract 16:1–11

    Google Scholar 

  39. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JFM et al and the PKDS009 Collaborative Study Group (1997) Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 48:363–368

    Article  Google Scholar 

  40. Antonini A, Poewe W (2006) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829

    Article  Google Scholar 

  41. Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G et al (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinemia. A multi-country, nested case-control study. Drug Saf 35:159–171

    Article  PubMed  Google Scholar 

  42. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6–9

    Article  CAS  PubMed  Google Scholar 

  43. Jähnichen S, Horowski R, Pertz HH (2008) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225–228

    Article  Google Scholar 

  44. Valassi E, Klibanski A, Biller BMK (2010) Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95:1025–1033

    Article  CAS  PubMed  Google Scholar 

  45. Steffensen C, Maegbaek ML, Laurberg P, Andersen M, Kistorp CMN, Norrelund H et al (2012) Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endocrinol Metab 97:1629–1634

    Article  CAS  PubMed  Google Scholar 

  46. Hamilton DK, Vance ML, Roulos PT, Laws ER (2005) Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8:53–60

    Article  PubMed  Google Scholar 

  47. Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166:779–786

    Article  CAS  PubMed  Google Scholar 

  48. Radwanska E, McGarrigle HH, Little V, Lawrence D, Saris S, Swyer GI (1979) Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin or bromocriptine. Fertil Steril 32:187–192

    CAS  PubMed  Google Scholar 

  49. Stalldecker G, Reynoso R, Piroli G, Cáceres N, DeNicola AF (1993) Effects of dopamine and tamoxifen on serum prolactin and nuclear estrogen receptors in rat anterior pituitaries. Neuroendocrinol Lett 15:389–395

    CAS  Google Scholar 

  50. Lamberts SWJ, Verleun T, Oosterom R (1982) Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 34:339–342

    Article  CAS  PubMed  Google Scholar 

  51. Volker W, Gehring WG, Berning R, Schmidt RC, Schneider J, von zur Mühlen A (1982) Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 101:491–500

    CAS  PubMed  Google Scholar 

  52. Yamashita M, Hirakawa T, Tashiro Y, Matsuda T, Kibe M, Fukushima T et al (1987) Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine. No Shinkei Geka 15:65–72

    CAS  PubMed  Google Scholar 

  53. Lasco A, Cannavò S, Gaudio A, Morabito N, Basile G, Nicita-Mauro V et al (2002) Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur J Endocrinol 147:461–465

    Article  CAS  PubMed  Google Scholar 

  54. Whitelaw BC, Dworakowska D, Thomas NQ, Barazi S, Riordan-Eva P, King AP et al (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol 76:877–886

    Article  CAS  Google Scholar 

  55. Jaquet P, Qouafik L, Saveanu A, Gunz G, Fina F, Dufour H et al (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268–3276

    CAS  PubMed  Google Scholar 

  56. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707–716

    Article  CAS  PubMed  Google Scholar 

  57. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD et al (2008) Somatostatinergic ligands in dopamine-sensitive and –resistant prolactinomas. Eur J Endocrinol 158:595–603

    Article  CAS  PubMed  Google Scholar 

  58. Fahlbusch R, Buchfelder M, Schrell U (1987) Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J Neurosurg 67:807–815

    Article  CAS  PubMed  Google Scholar 

  59. Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6:19–27

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, Chicago, IL, 60611, USA

    Mark E. Molitch

Authors
  1. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Molitch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molitch, M.E. Management of medically refractory prolactinoma. J Neurooncol 117, 421–428 (2014). https://doi.org/10.1007/s11060-013-1270-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1270-8

Keywords

Search

Navigation